- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Proteomics to Confirm Treatment Benefit in NSCLC
A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer (NSCLC), but only among patients who are likely to have a poor outcome with the latter treatment type.
Specifically, patients predicted to have poor survival outcomes with epidermal growth factor receptor—tyrosine kinase inhibitors (EGFR–TKI) according to the proteomic test survived a median 3 months longer when treated with chemotherapy than their counterparts who received the EGFR–TKI erlotinib.
By contrast, neither treatment regimen was associated with superior overall survival among patients whose predicted outcomes were good.
Original report: http://bit.ly/1jugCqX
Source: medwire News
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
